Lutetium-177-PSMA-617 in Oligo-metastatic Hormone-sensitive Prostate Cancer (BULLSEYE): A Trial Update. // European Urology Focus. – URL: https://www.sciencedirect.com/science/article/pii/S2405456926001665?dgcid=rss_sd_all
Lutetium-177-PSMA-617 in Oligo-metastatic Hormone-sensitive Prostate Cancer (BULLSEYE): A Trial Update. European Urology Focus. https://www.sciencedirect.com/science/article/pii/S2405456926001665?dgcid=rss_sd_all
“Lutetium-177-PSMA-617 in Oligo-metastatic Hormone-sensitive Prostate Cancer (BULLSEYE): A Trial Update.” European Urology Focus.
@article{article93800,
title = {Lutetium-177-PSMA-617 in Oligo-metastatic Hormone-sensitive Prostate Cancer (BULLSEYE): A Trial Update},
journal = {European Urology Focus},
url = {https://www.sciencedirect.com/science/article/pii/S2405456926001665?dgcid=rss_sd_all}
}
Objective To assess prostate‐specific antigen (PSA) testing according to income, age, and region of residence in Sweden. Patients and Methods We conducted a nationwide, population‐based open cohort study of men aged 40–90 years in...